CD38 bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B cell malignancies.
Green DJ et al.Blood. 2017 Nov 20. pii: blood-2017-09-807610. doi: 10.1182/blood-2017-09-807610. [Epub ahead of print].
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV et al. Cell Cycle. 2017 Nov 20:1-29. doi: 10.1080/15384101.2017.1403689. [Epub ahead of print].
A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
Offidani M et al. Future Oncol. 2017 Nov 1. doi: 10.2217/fon-2017-0371. [Epub ahead of print].
DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.
Leaf RK et al. J Immunother. 2017 Nov/Dec;40(9):315-322. doi: 10.1097/CJI.0000000000000185.